News
Latest News, Announcements, and Press Releases
24Nov 20
Codexis and Casdin Capital Launch SynBio Innovation Accelerator
REDWOOD CITY, Calif. and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading Synthetic Biology company developing and supplying differentiated enzyme products for high value markets, in collaboration with leading life science investor Casdin Capital,…
read more09Nov 20
Codexis to Participate at Three Virtual Investment Conferences in November
REDWOOD CITY, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate at three upcoming virtual investment conferences: Stifel Healthcare Conference on Monday, November 16, 2020 with…
read more05Nov 20
Codexis Reports Third Quarter 2020 Financial Results
Stronger than expected total revenues of $18.4 million delivered in the quarter Higher sequential sales expected again in the fourth quarter, showing growing momentum as we close 2020 Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif.…
read more29Oct 20
Codexis to Hold Third Quarter 2020 Conference Call on November 5
REDWOOD CITY, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after market close on Thursday, November 5, 2020 . Codexis management…
read more08Sep 20
Codexis to Present at Two Virtual Investment Conferences in September
REDWOOD CITY, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual investment conferences: H.C. Wainwright 22 nd Annual Global Investment Conference on…
read more06Aug 20
Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors
REDWOOD CITY, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announced the appointment of Jennifer L. Aaker , Ph.D. to its board of directors, expanding membership…
read more01Aug 20
Codexis Reports Second Quarter 2020 Financial Results
Revenues increased 21% to $15 million ; 72% rise in R&D revenue included a significant contribution from the Takeda biotherapeutics partnership Conference call with slides begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif. , Aug. 06, 2020 (GLOBE…
read more30Jul 20
Codexis to Hold Second Quarter 2020 Conference Call on August 6
REDWOOD CITY, Calif. , July 30, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020 . Codexis management…
read more23Jun 20
Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis
Partnership targets accelerating the commercialization of enzymatic DNA synthesis: Codexis invests cash and protein engineering for equity stake in Molecular Assemblies REDWOOD CITY, Calif. and SAN DIEGO , June 23, 2020 (GLOBE NEWSWIRE) — Codexis, Inc.
read more16Jun 20
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
REDWOOD CITY, Calif. , June 16, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore , Ph.D. and Stephen Dilly , MBBS,…
read moreSince 2002, Codexis has created new technologies to unlock the power of proteins®. Put our unmatched protein engineering expertise to work for you.
Unlock the power of proteins® with Codexis
Learn More
Company
Industries